Kriya Medical Technologies has received its manufacturing license from the DCGI (Drugs Controller General of India) for its product KRIVIDA Novus, an RT-PCR kit that can detect the Omicron variant and its sub-lineages in 45 minutes.

KRIVIDA Novus will be produced at Kriya’s state-of-the-art manufacturing facility in Oragadam in Chennai. The company currently has a production capacity of 5 million tests per month and plans to increase it to 10 million tests per month within the next two weeks.

Anu Moturi, CEO and Founder, Kriya Medical Technologies, said, “I thank the ICMR and DCGI for their swift action. Acquiring this license is yet another milestone and a step towards our vision of making good healthcare affordable and accessible to all. Our focus is to make testing for Covid-19 variants faster, affordable, and accessible to everyone, thereby enabling swift prevention and timely treatment. Since KRIVIDA Novus can detect the Omicron variant (B.1.1.529) and all its sub-lineages, such as BA.1, BA.2 and BA.3 in 45 minutes, it is most ideal and beneficial for entry point screening at airports and remobilization of normal conditions in the workplace and institutions.”

Priced at Rs 150 +taxes, the test is affordable and most suitable for entry point screening at airports. The kit is compatible with Real-Time PCR machines with a test run time of roughly 45 minutes. It provides an early report to aid diagnosis and also gives precise variants to enable appropriate treatment.